Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PHAR 253 Exam 2 > Managing S/E of AD's > Flashcards

Managing S/E of AD's Flashcards

1
Q

When do pts commonly experience Nauseau and stomach upset?

A

Very common (17-26%)
Majority of patients will experience this by 2nd week of treatment (up to 83%) and up to 3 months into therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Rate AD’s Nauseau

A

Venlafaxine > SSRI > Bupropion > Moclobemide > Mirtazapine (less, histamine blockade)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How can nauseau be managed?

A

Divide doses / reduce SSRI dose if patient stable
Take the medication with small amount of food (e.g. crackers)
? Ginger-containing food or beverages

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

When does diarhhea occur? Does it resolve?

A

May be transient and resolve within weeks
Most experience this by 2 weeks and some will have it persist up to 3 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Managemeng of Diarhhea?

A

Should resolve on its own
May use antidiarrheal agent (e.g., loperamide)
May wish to try probiotics and/or psyllium, etc.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

When should loperamid enot be taken?

A

If blood in the stool +/- fever, don’t take loperamide, risk of toxic mega colon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What AD”s cause the most constipation?

A

Paroxetine associated with highest rates of constipation out of all SSRIs
Common with TCAs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Management of Constipation?

A

Should resolve on its own (up to 3 months)
Adequate activity, fiber
OTC / self-care as normal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Which SSRI is associated with constipation (most)?

A

Paroxetine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What blackbox warning do AD’s have?

A

Current FDA (USA) black box warning of increased risk of suicidality in children, adolescents, and young adults (18-24) during initial therapy (first 1-2 months) with any antidepressant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What AD’s are most associated with suicidality?

A

Paroxetine and Venlafaxine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

In regards to sucidality, is there an association with age?

A

<18 –> possible association

> 18 –> Ambigous
–> Systematic review of observational studies that reported completed and attempted suicides showed there is a protective effect of SSRIs on suicidality in this age group

25-64 - Neutral-protective

> 65 –> Possible protective effect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What antidepressants are commonly associated with sexual dysfunction?

A

Antidepressants associated with an increased frequency of sexual dysfunction are:
SSRIs
TCAs
SNRIs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Which has the lowest risk of sexual dysfx?

A

Lowest risk: bupropion
Mirtazapine, trazodone, moclobemide typically lower risk
Vilazodone and vortioxetine appear to be lower risk as well

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Sexual Dysfx Management

A
  1. No intervention

Some case reports of spontaneous remission or improvement, although infrequently

This strategy may increase the risk of non-compliance among patients for whom sexual side effects are concerning

  1. Reduce
    Reducing doses of antidepressants to improve antidepressant-related sexual dysfunction while still maintaining efficacy as antidepressant
    Potential disadvantage = relapse
  2. Drug holidays or eliminating doses for a few days prior to sexual intercourse (not preferred)
    Some evidence of efficacy with sertraline, citalopram, and paroxetine
    Potential disadvantages = withdrawal side effects (especially venlafaxine) after missing more than 2 doses, relapse of depressive symptoms, and increasing patient non-adherence
  3. Using medications to augment sexual side effects

Adjunct anti-depressant (bupropion or mirtazapine)
Evidence is inconsistent - some studies show benefit and others do not

Sildenafil or tadalafil
Greatest evidence for men with anti-depressant induced erectile dysfunction (ED)
Efficacy in one trial was similar to those found in ED secondary to other causes

  1. Switching antidepressant
    Switch to an agent with lower rates of sexual side effects

Bupropion = greatest amount of evidence for successful treatment of AD-induced sexual dysfunction

Mirtazapine = some small RCTs show resolution of sexual dysfunction when switching to mirtazapine

SNRI instead of SSRI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

QT prolongation Risk, High and Low risk drugs

A

Generally safe at therapeutic doses

TCAs high risk especially at higher doses
Cital, escital, venla, desvenla, mirtaz – conditional/possible risk, esp with higher doses

Other SSRIs, bupropion, moclobemide may have lowest risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Risk factors for QT prolongation

A

Cardiomyopathy
M.I.
Long QT syndrome
Hypokalmeia
Hypomagnesemia
Age
Female Sex
Drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What causes serotonin syndrome?

A

Concomitant use of multiple serotonergic agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is serotonin syndrome described as?

A

Classically described as a “triad” of
mental status changes
autonomic hyperactivity
neuromuscular abnormalities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

TX of Serotonin Syndrome

A

Treatment: supportive, discontinue serotonergic agents, cyproheptadine serotonin antagonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

CAuse sof serotonin syndrome

A

Antidepressants: MAOIs, TCAs, venlafaxine, St. John’s Wort,
Others: linezolid, dextromethorphan, meperidine, tramadol, opioids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Which drugs are the worst for discontinuation syndrome?

A

venlafaxine, paroxetine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is the mechanism of disocntinuation syndrome?

A

Exact mechanism unknown, but multiple theories exist

24
Q

Who is more likely to have discontinuation syndrome?

A

More likely in those who have been on tx >6-8 weeks
Risk appears to also relate to affinity for serotonin transporter

25
Q

Rate SSRI discontinuation syndrome

A

Paroxetine > fluvoxamine, sertraline, citalopram > fluoxetine

26
Q

What does discontinuation syndrome present as?

A

F = flu-like symptoms fatigue, lethargy, malaise, muscle aches
I = Insomnia
N = Nausea
I = Imbalance
S = Sensory disturbances paresthesias (numbness), electric-shock sensations
H = Hyperarousal anxiety, agitation

27
Q

Describe symtpoms onset, duration of discontinuation syndrome?

A

Symptoms start 24-72 hours after AD stop

Generally mild and transient
But can be intolerable

Symptoms spontaneously resolve in 1-2 weeks
May persist for weeks to months for some patients

Be sure to counsel patients about this!
Especially once they have been taking it for a longer period of time (>6-8 weeks)

28
Q

How can discontinuation syndrome be prevented?

A

Reduce the dose over ~2-4 wks at the end of the tx

May be able to stop fluoxetine without taper due to long t1/2

29
Q

What to do if discontinuation syndrome occurs?

A

Consider restarting medication with a slow taper

If symptoms occur during tapering
–> Consider restarting at original dose and taper slower

If slow tapering is poorly tolerated
–> Consider substituting fluoxetine

30
Q

What should be monitored and followe dup on?

A

Adherence
Tolerability
Response
Sucidality

31
Q

What to do if symptoms of MDD persists?

A

If symptoms persist after an adequate trial of initial medication (6-8 weeks) at an adequate dose

switch to alternate first line agent

or

augment with an alternate mechanism antidepressant, Secondgeneration antipsych, or psychotherapy

32
Q

How many fail to achieve remission with intial pharmacotx?

A

2/3 will fail to achieve remission with initial pharmtx
> 30% will have a less than satisfactory response to 4 courses of antidepressants

33
Q

What are some factors to condier when switching or augmenting?

A

Augment–> PArtial repsonse, faster or synergistic response

Switch –> No response, less pill/cost burden, fewer A/e

34
Q

What is tx-resistant depresison?

A

Lack of improvement (<20% reduction in depression scores) following adequate trials of two or more antidepressants

35
Q

Is tx-resistance a type of depression?

A

NO

Consensus is that TRD is not a subtype of depression, but rather occurs along a spectrum from partial response to complete treatment resistance

36
Q

Options for tx-resistant depression

A

May switch antidepressant – again

May choose to use augmentation therapy
Lithium
Atypical antipsychotic
Thyroid (T3)
Other (buspirone, methylphenidate, modafinil) weak evidence

Or, combining antidepressants
SSRI/SNRI + mirtazapine
SSRI/SNRI + bupropion
SSRI + TCA

37
Q

When switching antidepressants, what are the ways to do it?

A

SSRI/SNRI within class: direct switch
May directly switch between SSRI<->SSRIs and between venlafaxine<->duloxetine due to similar mechanisms of action but often will cross taper

Other drugs: cross-tapering
Cross-tapering is recommended between drugs of different mechanisms of action

MAOIs: washout
Allow washout of 2 weeks when switching between MAOI and other antidepressants
5 weeks between stopping fluoxetine & starting MAOI

38
Q

What is lithiums role in MDD?

A

Has antidepressant effect (TRD) and is one of the most investigated augmentation strategy

Although, most evidence is in older studies that used TCAs and MAOIs; short duration of therapy

Should see response by 3-4 weeks
If patient responds, continue the combination for at least 6-9 months

39
Q

Role of Triiodothyronine (T3)

A

Improves and accelerates antidepressant effect in studies (TRD use)

Recommended trial is 2 weeks at 50mcg/day

Rarely stopped related to side effects
may cause tachycardia, insomnia, sweating

Caution in patients with cardiac insufficiency or elderly

May preferred over lithium due to better tolerance

40
Q

What atypical anti-psychotics may be used for TRD?

A

Ariprazole, Risperidone, Quietiapine, Olanzapine

Usually used at lower doses than used for schizophrenia or bipolar disorder

41
Q

When is maintenance phase tx recommended?

A

Maintenance Phase treatment is recommended for patients with chronic symptoms or with a history of 3 or more depressive episodes

42
Q

What is response?

A

If response to tx (50% ↓ in sxs) after 4 weeks of treatment, continue at an optimal dose (e.g. increase dose if indicated) and re-evaluate at 6, 8 and 12 weeks

43
Q

What is continuation phase?

A

Antidepressant should continue at the same dosage as required in Acute Phase for additional 4-9 months

44
Q

What is maintenance phase?

A

Duration is indefinite and may be lifelong
Factors to consider longer term maintenance treatment (> 2 yr)

45
Q

Depression Sx in Elderly

A

Anhedonia, cognitive impairment, decreased appetite, increased irritability

46
Q

Elderly TX onset and length

A

Less likely to achieve remission with greater chance of relapse: consider maintenance therapy
Symptoms may take longer to respond to tx (12 wk+)

47
Q

Starting Tx in elderly

A

Start low and go slow” – increased risk of a/e, comorbidities, D.I.

Monotherapy preferred over polypharmacy

48
Q

Difficulties of treating depression in elderly

A

↑ risk AEs, ↓ elimination, ↑ comorbidities, ↑ DIs

49
Q

What AD’s are on the BEER’s list?

A

SSRI, SNRI, TCA, mirtazapine on BEERS
Increased risk of falls, fractures, hyponatremia, hypotension
Extra caution with anticholinergic drugs

50
Q

What are better choices for elderly patients?

A

duloxetine, bupropion, sertraline

51
Q

How to manage depression in children/adolescants?

A

Emphasize: active monitoring rather than treatment right away (unless severe), supportive care

Psychological treatment strongly recommended as first-line (e.g. psychotherapy, counselling)

52
Q

AD”s in Children????

A

No AD approved by HC for use in < 18 yrs

FDA: fluoxetine, escitalopram

Off-label: sertraline, citalopram

Avoid SNRI, TCA (more susceptible to increased NE s/e)

AEs more common. Titrate slowly with close monitoring (esp suicidality)

53
Q

Depresison and Preganncy

A
54
Q

What is critical to understand about depression in preganncy?

A

Untreated, or undertreated, maternal depression poses significant risks to both the mother and child

  • Worsening sx, comprimise maternal and fetal health, maternal-infant bonding, and infant care post-partum

The risks of stopping often outweigh the risks associated with pharmacotherapy

Inconsistent findings related to risk of neonatal pulmonary HTN, congenital malformations, or spontaneous abortion

55
Q

AD’s in preganncy

A

SSRIs are 1st line in pregnancy; most safety data for sertraline, citalopram, escitalopram

Paroxetine may have higher risk of cardiac malformations in fetus
Less data: SNRI, mirtazapine, bupropion

56
Q

Breastfeeding AD’s

A

Citalopram, nortriptyline, sertraline, and paroxetine are 1st line in breastfeeding mothers, because they have low-to-undetectable serum concentrations (at therapeutic doses) in breast-fed infants/children

Breastfeeding generally not a contraindication to any ADs

PHAR 253 Exam 2 (4 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions